Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis

R. Wilson, P. Reimnitz, E. Operschall, J. Alder (London, United Kingdom; Wuppertal, Berlin, Germany; Montville, United States Of America)

Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Session: Treating bronchiectasis in respiratory patients
Session type: Oral Presentation
Number: 4645
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Wilson, P. Reimnitz, E. Operschall, J. Alder (London, United Kingdom; Wuppertal, Berlin, Germany; Montville, United States Of America). Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2013; 42: Suppl. 57, 4645

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014


Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016


Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007


Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016

Assessing response to treatment of exacerbations of bronchiectasis in adults
Source: Eur Respir J 2009; 33: 312-318
Year: 2009



Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013


A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013


Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013


Comparative analysis of the predictive utility of clinical disease severity scores for non-cystic fibrosis bronchiectasis
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014


DLCO predicts disease severity and mortality in patients with non-cystic fibrosis bronchiectasis
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015

Patients hospitalised with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics
Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma
Year: 2016

Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015


LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015


Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018


Prevalence of non-cystic fibrosis bronchiectasis in patients with severe asthma: a real-life study
Source: Virtual Congress 2020 – Air pollution and comorbidities
Year: 2020

A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014


Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002

Prolonged antibiotics for non-cystic fibrosis purulent bronchiectasis in children and adults: A Cochrane review
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013